About: The lysosome: A potential juncture between SARS‐CoV‐2 infectivity and Niemann‐Pick disease type C, with therapeutic implications

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The lysosome: A potential juncture between SARS‐CoV‐2 infectivity and Niemann‐Pick disease type C, with therapeutic implications Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The lysosome: A potential juncture between SARS‐CoV‐2 infectivity and Niemann‐Pick disease type C, with therapeutic implications
Creator	Sviridov, Dmitri Remaley, Alan Ballout, Rami Bukrinsky, I Michael, \|
Source	Medline; PMC
abstract	Drug repurposing is potentially the fastest available option in the race to identify safe and efficacious drugs that can be used to prevent and/or treat COVID‐19. By describing the life cycle of the newly emergent coronavirus, SARS‐CoV‐2, in light of emerging data on the therapeutic efficacy of various repurposed antimicrobials undergoing testing against the virus, we highlight in this review a possible mechanistic convergence between some of these tested compounds. Specifically, we propose that the lysosomotropic effects of hydroxychloroquine and several other drugs undergoing testing may be responsible for their demonstrated in vitro antiviral activities against COVID‐19. Moreover, we propose that Niemann‐Pick disease type C (NPC), a lysosomal storage disorder, may provide new insights into potential future therapeutic targets for SARS‐CoV‐2, by highlighting key established features of the disorder that together result in an “unfavorable” host cellular environment that may interfere with viral propagation. Our reasoning evolves from previous biochemical and cell biology findings related to NPC, coupled with the rapidly evolving data on COVID‐19. Our overall aim is to suggest that pharmacological interventions targeting lysosomal function in general, and those particularly capable of reversibly inducing transient NPC‐like cellular and biochemical phenotypes, constitute plausible mechanisms that could be used to therapeutically target COVID‐19.
has issue date	2020-05-05(xsd:dateTime)
bibo:doi	10.1096/fj.202000654r
bibo:pmid	32367579
has license	cc-by-nc-nd
sha1sum (hex)	c6ef4b35aa0339f3a42aa4004186d4a04ae3182c
schema:url	https://doi.org/10.1096/fj.202000654r
resource representing a document's title	The lysosome: A potential juncture between SARS‐CoV‐2 infectivity and Niemann‐Pick disease type C, with therapeutic implications
has PubMed Central identifier	PMC7383733
has PubMed identifier	32367579
schema:publication	FASEB J
resource representing a document's body	covid:c6ef4b35aa0339f3a42aa4004186d4a04ae3182c#body_text
is schema:about of	named entity 'potential' named entity 'Niemann-Pick disease' named entity 'cholesterol' named entity 'cathepsins' named entity 'lipid metabolism' named entity 'viral envelope' named entity 'endocytosed' named entity 'SARS-CoV-2' named entity 'antimicrobial activity' named entity 'antimicrobial therapy' named entity 'chloroquine' named entity 'cholesterol levels' named entity 'lysosome' named entity 'COVID-19' named entity 'NPC1' named entity 'macrolide antibiotic' named entity 'adenosine' named entity 'enzyme' named entity 'infectivity' named entity 'chloroquine' named entity 'posaconazole' named entity 'phenotype' named entity 'plasma membrane' named entity 'host cells' named entity 'lysosomes' named entity 'ACE2' named entity 'cyclodextrin' named entity 'ribose' named entity 'coronavirus' named entity 'anti-inflammatory' named entity 'chloroquine' named entity 'phenocopy' named entity 'intracellular' named entity 'transmembrane serine protease 2' named entity 'ACE2' named entity 'membrane proteins' named entity 'NPC1' named entity 'cross-reacts' named entity 'viral envelope' named entity 'COVID' named entity 'sphingolipids' named entity 'mode of action' named entity 'protein' named entity 'lysosome' named entity 'alkalinizes' named entity 'NPC1' named entity 'lysosomal' named entity 'viral replication' named entity 'lysosome' named entity 'protein' named entity 'TMPRSS2' named entity 'biochemical' named entity 'protein' named entity 'cholesterol' named entity 'SARS-CoV-2' named entity 'lipid rafts' named entity 'ACE2' named entity 'remdesivir' named entity 'cholesterol' named entity 'antifungals' named entity 'SARS-CoV-2' named entity 'azithromycin' named entity 'TMPRSS2' named entity 'chloroquine' named entity 'plasma membrane' named entity 'viral pathogen' named entity 'SARS-CoV-2' named entity 'lysosomal enzymes' named entity 'intracellular' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'intracellular' named entity 'azithromycin' named entity 'plasma membrane' named entity 'synergistic' named entity 'N-glycosylated'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software